# Study of EV for Recurrent Endometrial Carcinoma

> **NCT07139977** · PHASE2 · NOT_YET_RECRUITING · sponsor: **William Bradley** · enrollment: 12 (estimated)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** Enfortumab Vedotin

## Key facts

- **NCT ID:** NCT07139977
- **Lead sponsor:** William Bradley
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2027-11-30
- **Final completion:** 2028-05-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07139977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07139977, "Study of EV for Recurrent Endometrial Carcinoma". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT07139977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*